These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23810823)

  • 21. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
    Venkatesan S; Swanton C; Taylor BS; Costello JF
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.
    Das Thakur M; Stuart DD
    Clin Cancer Res; 2014 Mar; 20(5):1074-80. PubMed ID: 24352648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
    Montor WR; Salas AROSE; Melo FHM
    Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Challenges in Cancer Treatment.
    Zugazagoitia J; Guedes C; Ponce S; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Clin Ther; 2016 Jul; 38(7):1551-66. PubMed ID: 27158009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRKing down an old oncogene in a new era of targeted therapy.
    Vaishnavi A; Le AT; Doebele RC
    Cancer Discov; 2015 Jan; 5(1):25-34. PubMed ID: 25527197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative omics analyses broaden treatment targets in human cancer.
    Sengupta S; Sun SQ; Huang KL; Oh C; Bailey MH; Varghese R; Wyczalkowski MA; Ning J; Tripathi P; McMichael JF; Johnson KJ; Kandoth C; Welch J; Ma C; Wendl MC; Payne SH; Fenyö D; Townsend RR; Dipersio JF; Chen F; Ding L
    Genome Med; 2018 Jul; 10(1):60. PubMed ID: 30053901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
    Comoglio PM; Trusolino L; Boccaccio C
    Nat Rev Cancer; 2018 Jun; 18(6):341-358. PubMed ID: 29674709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polypharmacology in Precision Oncology: Current Applications and Future Prospects.
    Antolin AA; Workman P; Mestres J; Al-Lazikani B
    Curr Pharm Des; 2016; 22(46):6935-6945. PubMed ID: 27669965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
    McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
    Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
    Knudsen ES; Witkiewicz AK
    Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
    Yeang CH; Beckman RA
    Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
    Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Targeted Therapy for Tumors with
    Kheder ES; Hong DS
    Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Heterogeneity and Therapeutic Resistance.
    Lovly CM; Salama AK; Salgia R
    Am Soc Clin Oncol Educ Book; 2016; 35():e585-93. PubMed ID: 27249771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.